X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs WOCKHARDT LTD. - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB WOCKHARDT LTD. DR. REDDYS LAB/
WOCKHARDT LTD.
 
P/E (TTM) x 28.6 -23.5 - View Chart
P/BV x 3.1 2.4 128.8% View Chart
Dividend Yield % 0.9 0.0 53,039.7%  

Financials

 DR. REDDYS LAB   WOCKHARDT LTD.
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
WOCKHARDT LTD.
Mar-18
DR. REDDYS LAB/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs2,7881,012 275.5%   
Low Rs1,902532 357.8%   
Sales per share (Unadj.) Rs860.8355.9 241.9%  
Earnings per share (Unadj.) Rs57.1-60.3 -94.7%  
Cash flow per share (Unadj.) Rs122.0-46.8 -260.9%  
Dividends per share (Unadj.) Rs20.000.01 200,000.0%  
Dividend yield (eoy) %0.90 65,825.1%  
Book value per share (Unadj.) Rs757.7257.8 293.9%  
Shares outstanding (eoy) m165.91110.63 150.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.72.2 125.6%   
Avg P/E ratio x41.1-12.8 -320.9%  
P/CF ratio (eoy) x19.2-16.5 -116.5%  
Price / Book Value ratio x3.13.0 103.4%  
Dividend payout %35.00 -211,251.4%   
Avg Mkt Cap Rs m389,03485,379 455.7%   
No. of employees `00023.56.3 376.1%   
Total wages/salary Rs m32,1499,371 343.1%   
Avg. sales/employee Rs Th6,070.86,295.0 96.4%   
Avg. wages/employee Rs Th1,366.61,498.3 91.2%   
Avg. net profit/employee Rs Th402.5-1,066.3 -37.7%   
INCOME DATA
Net Sales Rs m142,81039,369 362.7%  
Other income Rs m1,5521,202 129.1%   
Total revenues Rs m144,36240,571 355.8%   
Gross profit Rs m23,51218 128,480.9%  
Depreciation Rs m10,7721,495 720.4%   
Interest Rs m7882,555 30.8%   
Profit before tax Rs m13,504-2,830 -477.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m4,380257 1,704.3%   
Profit after tax Rs m9,468-6,669 -142.0%  
Gross profit margin %16.50 35,418.8%  
Effective tax rate %32.4-9.1 -357.1%   
Net profit margin %6.6-16.9 -39.1%  
BALANCE SHEET DATA
Current assets Rs m104,98433,796 310.6%   
Current liabilities Rs m68,93826,917 256.1%   
Net working cap to sales %25.217.5 144.5%  
Current ratio x1.51.3 121.3%  
Inventory Days Days7479 93.7%  
Debtors Days Days10489 116.1%  
Net fixed assets Rs m104,38539,664 263.2%   
Share capital Rs m830553 150.0%   
"Free" reserves Rs m124,88627,968 446.5%   
Net worth Rs m125,71628,522 440.8%   
Long term debt Rs m25,08921,731 115.5%   
Total assets Rs m225,44381,620 276.2%  
Interest coverage x18.1-0.1 -16,868.7%   
Debt to equity ratio x0.20.8 26.2%  
Sales to assets ratio x0.60.5 131.3%   
Return on assets %4.5-5.0 -90.3%  
Return on equity %7.5-23.4 -32.2%  
Return on capital %9.7-7.7 -126.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,6239,807 740.5%   
Fx outflow Rs m18,9161,789 1,057.6%   
Net fx Rs m53,7078,019 669.8%   
CASH FLOW
From Operations Rs m18,030684 2,634.4%  
From Investments Rs m-14,8836,302 -236.1%  
From Financial Activity Rs m-4,440-7,695 57.7%  
Net Cashflow Rs m-1,236-664 186.1%  

Share Holding

Indian Promoters % 25.5 74.5 34.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 2.3 234.8%  
FIIs % 35.3 7.7 458.4%  
ADR/GDR % 18.5 0.1 18,500.0%  
Free float % 15.3 15.4 99.4%  
Shareholders   75,885 67,757 112.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  ABBOTT INDIA  PANACEA BIOTECH  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal & Realty Stocks Drag(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.1% while the Hang Seng is down 0.5%.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 16, 2018 11:53 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - AJANTA PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS